阿霉素心肌病
Doxorubicin cardiomyopathy.
作者信息
Chatterjee Kanu, Zhang Jianqing, Honbo Norman, Karliner Joel S
机构信息
Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242-1081, USA. kanu-chatterjee @ uiowa.edu
出版信息
Cardiology. 2010;115(2):155-62. doi: 10.1159/000265166. Epub 2009 Dec 11.
Abstract
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.
摘要
已确诊的阿霉素性心肌病是一种致命疾病。当出现充血性心力衰竭时，死亡率约为50%。为了解阿霉素性心肌病的机制和病理生理学，人们已经进行了广泛研究，并积累了大量知识和经验。不幸的是，目前尚无针对已确诊的阿霉素性心肌病的有效治疗方法。为了发现预防性治疗方法，人们已经进行了广泛研究，并且仍在进行相关研究。然而，尚未发现一种有效且可临床应用的预防性治疗方法。
相似文献
1
Doxorubicin cardiomyopathy.
Cardiology. 2010;115(2):155-62. doi: 10.1159/000265166. Epub 2009 Dec 11.
2
Recovery from anthracycline cardiomyopathy--how can it be explained?
J Heart Lung Transplant. 2009 Jul;28(7):751. doi: 10.1016/j.healun.2009.04.001. Epub 2009 May 6.
3
Doxorubicin-induced cardiomyopathy.
N Engl J Med. 1998 Sep 24;339(13):900-5. doi: 10.1056/NEJM199809243391307.
4
[Drug-induced myocarditis and cardiomyopathy].
Nihon Rinsho. 2012 Aug;70 Suppl 6:589-92.
5
Anthracycline-induced cardiomyopathy in children: a report of six cases.
Med Pediatr Oncol. 1984;12(1):54-8. doi: 10.1002/mpo.2950120113.
6
Doxorubicin-induced cardiomyopathy.
N Engl J Med. 1999 Feb 25;340(8):653-4; author reply 655. doi: 10.1056/NEJM199902253400813.
7
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21.
8
Mechanisms and management of doxorubicin cardiotoxicity.
Herz. 2011 Jun;36(4):296-305. doi: 10.1007/s00059-011-3470-3.
9
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
J Pharm Pharmacol. 2004 Jun;56(6):757-68. doi: 10.1211/0022357023565.
10
Doxorubicin-induced cardiomyopathy.
N Engl J Med. 1999 Feb 25;340(8):654-5.
引用本文的文献
1
In vitro evaluation of CeO nanoparticles on doxorubicin induced cardiotoxicity: focused on oxidative stress, inflammation, apoptosis, and mitochondrial function.
Daru. 2025 Sep 3;33(2):30. doi: 10.1007/s40199-025-00573-y.
2
Circular RNAs in Heart Diseases.
Adv Exp Med Biol. 2025;1485:255-271. doi: 10.1007/978-981-96-9428-0_17.
3
Methylene Blue Mitigates Doxorubicin-Induced Cardiotoxicity via KEAP1/NRF2/GPX-4/Caspase3 Modulation.
Int J Mol Sci. 2025 Aug 8;26(16):7680. doi: 10.3390/ijms26167680.
4
Predicting bone cancer drugs properties through topological indices and machine learning.
Sci Rep. 2025 Aug 24;15(1):31150. doi: 10.1038/s41598-025-16497-1.
5
Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity.
Front Oncol. 2025 Jul 16;15:1621409. doi: 10.3389/fonc.2025.1621409. eCollection 2025.
6
Combined effects of metformin and coenzyme Q10 on doxorubicin-induced cardiotoxicity in male wistar rats.
Sci Rep. 2025 Jul 1;15(1):20725. doi: 10.1038/s41598-025-07576-4.
7
Reliability and applicability of the and heart rate kinetics during moderate-intensity cycling in immunotherapy patients and healthy controls.
Eur J Appl Physiol. 2025 Jun 9. doi: 10.1007/s00421-025-05845-8.
8
Multisymptom Burden in Cancer Survivors: Benefits of Physical Activity.
Exerc Sport Mov. 2024 Fall;2(4). doi: 10.1249/esm.0000000000000029.
9
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology.
Pharmaceuticals (Basel). 2025 May 3;18(5):681. doi: 10.3390/ph18050681.
10
A narrative review of metabolomics approaches in identifying biomarkers of doxorubicin-induced cardiotoxicity.
Metabolomics. 2025 May 17;21(3):68. doi: 10.1007/s11306-025-02258-8.
本文引用的文献
1
Chemotherapy and cardiotoxicity.
Rev Cardiovasc Med. 2008 Spring;9(2):75-83.
2
Vincristine attenuates doxorubicin cardiotoxicity.
Biochem Biophys Res Commun. 2008 Sep 5;373(4):555-60. doi: 10.1016/j.bbrc.2008.06.067. Epub 2008 Jun 30.
3
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.
Can J Cardiol. 2008 Jan;24(1):21-40. doi: 10.1016/s0828-282x(08)70545-2.
4
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.
Cancer Res. 2007 Nov 1;67(21):10428-35. doi: 10.1158/0008-5472.CAN-07-1344.
5
Acute vincristine pretreatment protects adult mouse cardiac myocytes from oxidative stress.
J Mol Cell Cardiol. 2007 Sep;43(3):327-36. doi: 10.1016/j.yjmcc.2007.06.005. Epub 2007 Jun 21.
6
Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.
Prog Cardiovasc Dis. 2007 Mar-Apr;49(5):330-52. doi: 10.1016/j.pcad.2006.10.002.
7
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62. doi: 10.1016/j.jacc.2006.07.052. Epub 2006 Nov 9.
8
The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity.
Cardiovasc Res. 2006 Jan;69(1):186-97. doi: 10.1016/j.cardiores.2005.07.012. Epub 2005 Sep 12.
9
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Circulation. 2005 Apr 5;111(13):1601-10. doi: 10.1161/01.CIR.0000160359.49478.C2.
10
Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy.
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1925-30. doi: 10.1152/ajpheart.01054.2004.
Zotero 插件